These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 23391109)

  • 21. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver.
    Chung MH; Pisegna J; Spirt M; Giuliano AE; Ye W; Ramming KP; Bilchik AJ
    Surgery; 2001 Dec; 130(6):954-62. PubMed ID: 11742323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.
    Oberg K
    Expert Rev Anticancer Ther; 2009 May; 9(5):557-66. PubMed ID: 19445573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma.
    Yao JC
    Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):163-72. PubMed ID: 17382271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials.
    Cives M; Soares HP; Strosberg J
    Curr Opin Oncol; 2016 Jul; 28(4):359-66. PubMed ID: 27138571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors.
    Hauser H; Gerson DS; Reidy-Lagunes D; Raj N
    Curr Treat Options Oncol; 2019 Nov; 20(12):87. PubMed ID: 31776785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carcinoid and neuroendocrine tumors: building on success.
    Kunz PL
    J Clin Oncol; 2015 Jun; 33(16):1855-63. PubMed ID: 25918282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New treatment strategies in advanced neuroendocrine tumours.
    Walter T; Brixi-Benmansour H; Lombard-Bohas C; Cadiot G
    Dig Liver Dis; 2012 Feb; 44(2):95-105. PubMed ID: 21983252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current medical treatment of pancreatic neuroendocrine tumors.
    Yalcin S; Oyan B; Bayraktar Y
    Hepatogastroenterology; 2007; 54(73):278-84. PubMed ID: 17419276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metastatic carcinoid tumor: changing patterns of care over two decades.
    Townsend A; Price T; Yeend S; Pittman K; Patterson K; Luke C
    J Clin Gastroenterol; 2010 Mar; 44(3):195-9. PubMed ID: 19609217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors.
    Pavel ME; Wiedenmann B
    Horm Metab Res; 2011 Nov; 43(12):844-53. PubMed ID: 22105475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Digestive neuroendocrine tumors (DNET): the era of targeted therapies.
    Boussaha T; Rougier P; Taieb J; Lepere C
    Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):134-41. PubMed ID: 23562338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New perspectives in the treatment of neuroendocrine tumours.
    Bajetta E; Catena L; Valente M; Bianco N; Bellomo F; Bombardieri E
    Anticancer Res; 2012 Oct; 32(10):4193-200. PubMed ID: 23060539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas.
    Reubi JC; Kvols LK; Waser B; Nagorney DM; Heitz PU; Charboneau JW; Reading CC; Moertel C
    Cancer Res; 1990 Sep; 50(18):5969-77. PubMed ID: 2168286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group.
    di Bartolomeo M; Bajetta E; Buzzoni R; Mariani L; Carnaghi C; Somma L; Zilembo N; di Leo A
    Cancer; 1996 Jan; 77(2):402-8. PubMed ID: 8625251
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastroenteropancreatic neuroendocrine tumors: update on therapeutics.
    Ganetsky A; Bhatt V
    Ann Pharmacother; 2012 Jun; 46(6):851-62. PubMed ID: 22589450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Islet cell carcinoma: neuroendocrine tumors of the pancreas and periampullary region.
    Nakakura EK; Bergsland EK
    Hematol Oncol Clin North Am; 2007 Jun; 21(3):457-73; viii. PubMed ID: 17548034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging therapies for advanced gastroenteropancreatic neuroendocrine tumors.
    Gupta S; Engstrom PF; Cohen SJ
    Clin Colorectal Cancer; 2011 Dec; 10(4):298-309. PubMed ID: 21813338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Drug therapy for neuroendocrine tumours].
    Tóth M
    Orv Hetil; 2013 Sep; 154(39):1556-64. PubMed ID: 24058101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity.
    Garbrecht N; Anlauf M; Schmitt A; Henopp T; Sipos B; Raffel A; Eisenberger CF; Knoefel WT; Pavel M; Fottner C; Musholt TJ; Rinke A; Arnold R; Berndt U; Plöckinger U; Wiedenmann B; Moch H; Heitz PU; Komminoth P; Perren A; Klöppel G
    Endocr Relat Cancer; 2008 Mar; 15(1):229-41. PubMed ID: 18310290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors.
    Cloyd JM; Konda B; Shah MH; Pawlik TM
    Expert Rev Clin Pharmacol; 2019 Feb; 12(2):101-108. PubMed ID: 30582383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.